Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis
about
sameAs
Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activitiesMap-ISODATA demarcates regional response to combination rt-PA and 7E3 F(ab')2 treatment of embolic stroke in the rat.Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface.Efficacy of a new mutated recombinant tissue-type plasminogen activator in beagles with acute coronary artery thrombiFunctional factor XIII-A is exposed on the stimulated platelet surfacePlatelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke.Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove!Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion modelAcute vertebrobasilar occlusion: current treatment strategies.Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?Rationale for intracoronary administration of abciximab.Side view thrombosis microfluidic device with controllable wall shear rate and transthrombus pressure gradient.Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stabilityAcute stroke therapy 1981-2009.Plasma and cellular contributions to fibrin network formation, structure and stability.The management of thrombotic lesions in the cardiac catheterization laboratory.Reduced clot retraction rate and altered platelet energy production in patients with asthma.α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis.Polyphosphate: physiologic? Pathologic? Pharmacologic?Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.Platelets inhibit the lysis of pulmonary microemboli.Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure.The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome.Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots.Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke.Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications.Fibrinogen and Fibrin in Hemostasis and Thrombosis.Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction
P2860
Q28222482-1040AC11-9F7C-44C1-813A-454429E6E41AQ30990244-59128E54-A3A1-4719-A47F-4A4CFACAF752Q33381505-75EED6FC-6CEC-4EC7-BB88-C41CD33993D7Q34031962-508F4A3D-CF6E-489D-AC92-B07596EB5510Q35023065-59B34C7D-020B-4D89-BFA0-EF1310A06814Q35052741-176FD82D-3A36-4BF3-8D87-8FB6F6A1ACECQ35945662-9CDF2F50-360C-4D01-A583-A3F05D46B79FQ36237842-342CF801-F898-4548-92D8-D4521DCB1C08Q36273731-B3DA0AA3-55E4-4A42-BBDF-CF7B864D8FD4Q36557600-91A7EBBA-9378-43BE-BA03-49BE986A9008Q36679440-D8D058F9-9471-43B9-B856-2783E7FFC876Q36865573-12802FAA-70DD-419A-9F11-6F3B710A623FQ36927583-FCB1DE42-6934-4F07-89D1-88D14A5ABDFBQ37138914-48CC0C44-8A94-4994-8FA5-703EDC9E59E1Q37450566-0E0C1835-91AD-49CC-BF1F-0D607891817AQ37564109-157BBD10-F1B8-489B-8D7E-A146CC05D335Q37768478-22FCCB6B-7408-42BC-BACC-8D083CD5E489Q37947959-9034D5CB-54C0-407C-9DA4-3327670F0634Q39795377-2AD0A85F-1C17-4F84-BCE1-59A4CC9062F8Q41228470-26858B9A-E832-4E57-8452-B78E85169097Q41807862-78109C14-9E41-4ABF-AB61-61DA0C437262Q43562848-D6B952A6-84CF-4967-802D-5EA4787C54C0Q43882361-87FD0F77-43BE-4C9E-AF05-16C0E12F578BQ44372590-8E68063A-1348-494F-9A1F-291C349C1F7DQ45842157-87C59F40-4BFE-4F96-A12A-2F692BAE9022Q45957006-A64CF68F-D385-45D2-8144-B2FF623F22BEQ49954181-A59B5FF4-E729-43B0-9875-EC7F0770DCC2Q52020290-C2C14987-6281-4BDC-84BB-C0399FC7E714Q52148831-3F443D4A-1EA8-47E2-B1D4-1B74BBA39706Q52650313-8CA56A18-969C-4D08-9009-00CEFE1CF825Q54842287-11D82C2F-0F73-43DA-85F9-00A7ADC82AD5Q57448701-0F1226F9-6956-4E71-9F0A-AA3CAFE1B258
P2860
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@ast
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@en
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@nl
type
label
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@ast
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@en
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@nl
prefLabel
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@ast
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@en
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@nl
P2093
P356
P1476
Disaggregation of in vitro pre ...... sure and promotes fibrinolysis
@en
P2093
P356
10.1161/01.ATV.21.1.142
P407
P577
2001-01-01T00:00:00Z